|
149 |
All The Ways Global Biopharma Still Grapples With Annex 1
|
관리자 |
2026-05-06 |
852 |
|
148 |
The Capacity Myth—and What Actually Matters
|
관리자 |
2026-02-27 |
1,528 |
|
147 |
Process Engineering's Key Role In Sterile Injectable Facility Design
|
관리자 |
2026-02-27 |
1,433 |
|
146 |
When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
|
관리자 |
2026-02-27 |
1,021 |
|
145 |
How to Design Your Pharmaceutical Facility Disinfection Programme Cleanroom
|
관리자 |
2026-01-30 |
2,092 |
|
144 |
Why Use Total Organic Carbon Analysis For Cleaning Validation?
|
관리자 |
2026-01-30 |
1,128 |
|
143 |
Building Enterprise Resilience From QRM Signals
|
관리자 |
2026-01-30 |
1,159 |
|
142 |
Contamination Control Strategies In Low Bioburden Biologic Drug Substance Manufacturing
|
관리자 |
2026-01-05 |
1,716 |
|
141 |
What 2025 FDA Warning Letters Tell Us About GMP Compliance
|
관리자 |
2026-01-05 |
1,217 |
|
140 |
EU Reaches Landmark on Reform of Pharmaceutical Legislation
|
관리자 |
2026-01-05 |
1,166 |